Patent ID: 7326690

Claim:
A method for modulating metabolic distress, comprising administering to a subject a therapeutically effective amount of a phthalazinedione or its pharmaceutically acceptable salt, ester, solvate, hydrate, metabolite, enantiomer, isomer, tautomer, amide, prodrug, or free base in treating a condition selected from the group consisting of multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome, Friedreich ataxia, Machado-Joseph disorder, progressive supranuclear palsy, Guillain-Barrê syndrome, Hodgkin's disease, Wegener's granulomatosis, systemic lupus erythematosus, scleroderma, Lyme disease, auricular or atrial fibrillation, thromboangiitis obliterans, peritonitis, hantavirus pulmonary syndrome, Wiskott-Aldrich syndrome, and preexcitation syndrome.